Illumina SEC filings document the company’s genomics technology business, financial results, governance and capital actions. Form 8-K reports cover quarterly and annual operating results, preliminary financial updates, share repurchase authorization, management and board changes, and Regulation FD disclosures.
The filing record also includes definitive proxy materials for annual meeting matters, director elections, compensation and shareholder voting. Material-event filings document completed acquisition activity, including the purchase of SomaLogic and Sengenics aptamer-based and functional proteomics assets, along with exhibits, common-stock repurchase disclosures and other capital-structure records.
ILLUMINA, INC. (ILMN) is the issuer for which Corvex Management filed a notice under Rule 144 to sell common stock. Corvex, an affiliate of a director, plans to sell up to 200,000 shares of Illumina common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $44,968,000, on or after August 27, 2026, on the Nasdaq Stock Market. Illumina had 151,000,000 shares outstanding of common stock for context. Corvex states it may be deemed the beneficial owner of shares held by funds it advises, and that the shares to be sold were purchased in various open market transactions between October 25, 2023 and March 27, 2025. The notice also lists multiple prior sales of Illumina shares by Corvex-managed entities during the past three months.
ILLUMINA, INC. (ILMN) is the issuer of common stock that an investment fund advised by Corvex Management, an affiliate of an Illumina director, plans to sell under Rule 144. The planned sale covers 300,000 shares of common stock, with an aggregate market value of $66,966,000.00, to be executed through Goldman Sachs & Co. LLC. Illumina reports 151,000,000 shares outstanding of this class as of the notice, which is a baseline figure, not the amount being sold.
Corvex-linked entities have reported multiple sales of Illumina common stock in the past three months, including 220,000 shares on May 28, 2026 for $34,686,783.32 and 457,858 shares on August 4, 2026 for $91,616,949.73. The shares now to be sold were purchased in various open market transactions between October 25, 2023 and March 27, 2025.
ILLUMINA, INC. (ILMN) director Keith A. Meister, through private investment funds advised by Corvex Management LP, reported indirect open‑market sales of a total of 679,574 shares of Illumina common stock on August 19–21, 2026, across multiple trades at weighted average prices within ranges from $201.59 to $220.43 per share. Corvex and Mr. Meister each disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest. A separate holding entry shows 6,780 shares of Illumina common stock held directly.
ILLUMINA, INC. (ILMN) received a notice that Corvex Management, an affiliate of an Illumina director, has filed to sell 250,000 shares of Illumina common stock under Rule 144. The shares are to be sold through Goldman Sachs & Co. LLC, with an aggregate market value of $53,310,000.00 and Illumina having 151,000,000 shares outstanding. The shares to be sold were purchased in various open market transactions between October 25, 2023 and March 27, 2025. Corvex has also reported multiple sizeable Illumina share sales over the past three months.
ILLUMINA, INC. (ILMN) executive Jakob Wedel Christensen, SVP, Strategy/Corp Development, reported selling 1,033 shares of common stock on 2026-08-18 at $191.52 per share in an open-market or private transaction. After this trade, he directly holds 14,023 shares. The transaction was affirmed as made under a Rule 10b5-1 trading plan.
ILLUMINA, INC. (ILMN) has a notice under Rule 144 for a planned resale of its Common Stock by Corvex Management, an affiliate of Illumina director Keith Meister. Corvex indicates an intent to sell 355,000 shares, with an aggregate market value of approximately $72,775,000, through Goldman Sachs & Co. LLC after 08/20/2026.
Corvex also reports prior open-market sales over the past three months totaling several hundred thousand Illumina shares across multiple transactions.
Illumina, Inc. (ILMN) received a Rule 144 notice from Jakob Wedel covering a planned sale of its common stock. The notice lists 1,033 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, with an aggregate value of $199,508.46, and references trading on NDAQ. The securities to be sold include shares underlying Restricted Stock Units with a listed date of 02/17/2026, and a proposed sale date of 08/18/2026.
Illumina, Inc. reported completion of a public debt offering of $300,000,000 aggregate principal amount of 4.950% notes due 2029. The notes were issued under an existing Indenture with U.S. Bank Trust Company, National Association, and were registered on a Form S-3 shelf registration.
Illumina expects to use the net proceeds from this offering, together with cash on hand, to repay its 4.650% notes due September 9, 2026, of which $500 million aggregate principal amount was outstanding as of June 28, 2026. The new notes accrue interest at 4.950% per annum, payable semi-annually, and mature on September 19, 2029. The company may redeem the notes, in whole or in part, at specified redemption prices and on terms set forth in the note documentation, and the notes may be accelerated upon an Event of Default as defined in the Indenture.
Illumina, Inc. entered into a new $1,000 million senior unsecured revolving credit facility with a syndicate of lenders and Bank of America, N.A. as administrative agent, issuing bank and swingline lender. The facility includes a $50 million swingline sublimit and a $75 million letter of credit sublimit.
Borrowings will bear a variable interest rate based on term SOFR or an alternate base rate, plus a margin that varies with Illumina’s debt rating. The agreement permits Illumina, subject to lender consent and conditions, to increase commitments or add term loans by up to $500 million. The facility matures on August 13, 2031 and may be extended for up to three additional one-year periods. It contains a maximum total leverage ratio covenant and operating covenants limiting subsidiary indebtedness, liens, fundamental changes and asset dispositions. Amounts may be prepaid and commitments terminated at any time without premium or penalty, and there were no borrowings outstanding as of the date referenced. This facility replaces and terminates the company’s prior 2023 credit agreement.
Illumina, Inc. is offering $300,000,000 aggregate principal amount of 4.950% Notes due 2029. The senior unsecured Notes pay interest semiannually on March 19 and September 19, beginning March 19, 2027, and mature on September 19, 2029. They will be issued in minimum denominations of $2,000 and will not be listed on any securities exchange.
Illumina expects net proceeds of about $297 million, to be used with cash on hand to repay its $500.0 million 4.650% notes due September 9, 2026. As of June 28, 2026, Illumina had $2.0 billion of total debt, including four other $500.0 million note issues, and no secured debt outstanding.
The Notes are senior unsecured obligations ranking equally with Illumina’s other unsecured senior debt and structurally subordinated to obligations of its subsidiaries, which had about $831 million of liabilities as of June 28, 2026. Illumina may redeem the Notes at its option (including a par call from August 19, 2029), and must offer to repurchase them at 101% plus accrued interest upon a Change of Control Triggering Event.